{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:41:42Z","timestamp":1793828502336,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of \u22655% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.<\/jats:p>","DOI":"10.1038\/s41408-021-00587-0","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T12:08:02Z","timestamp":1638446882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":181,"title":["Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-1676","authenticated-orcid":false,"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-1195","authenticated-orcid":false,"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7680-3254","authenticated-orcid":false,"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1708-7344","authenticated-orcid":false,"given":"Suzanne","family":"Lentzch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Badros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6sta","family":"Gahrton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-1573","authenticated-orcid":false,"given":"Sascha","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-2531","authenticated-orcid":false,"given":"Baldeep","family":"Wirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3677-4804","authenticated-orcid":false,"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jes\u00fas San","family":"Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"Dec","key":"587_CR1","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/0002-9343(87)90942-9","volume":"83","author":"P Noel","year":"1987","unstructured":"Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83(Dec):1062\u20138.","journal-title":"Am J Med"},{"issue":"May","key":"587_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/archinte.133.5.813","volume":"133","author":"RA Kyle","year":"1974","unstructured":"Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974;133(May):813\u20138.","journal-title":"Arch Intern Med"},{"key":"587_CR3","doi-asserted-by":"crossref","unstructured":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749\u201357.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"issue":"Mar","key":"587_CR4","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bjh.15092","volume":"180","author":"A Jurczyszyn","year":"2018","unstructured":"Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grzasko N, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018;180(Mar):831\u20139.","journal-title":"Br J Haematol"},{"issue":"Aug","key":"587_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","volume":"124","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124(Aug):907\u201312.","journal-title":"Blood"},{"issue":"Feb","key":"587_CR6","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood.V93.3.1032","volume":"93","author":"R Garcia-Sanz","year":"1999","unstructured":"Garcia-Sanz R, Orfao A, Gonzalez M, Tabernero MD, Blade J, Moro MJ, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(Feb):1032\u20137.","journal-title":"Blood"},{"issue":"Dec","key":"587_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1365-2141.1994.tb05114.x","volume":"88","author":"MA Dimopoulos","year":"1994","unstructured":"Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol. 1994;88(Dec):754\u20139.","journal-title":"Br J Haematol"},{"issue":"Dec","key":"587_CR8","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0889-8588(05)70125-8","volume":"13","author":"J Blade","year":"1999","unstructured":"Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol\/Oncol Clin North Am. 1999;13(Dec):1259\u201372.","journal-title":"Hematol\/Oncol Clin North Am"},{"issue":"Apr","key":"587_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"C Fernandez de Larrea","year":"2013","unstructured":"Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(Apr):780\u201391.","journal-title":"Leukemia"},{"issue":"Feb","key":"587_CR10","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/cncr.31718","volume":"125","author":"R Mina","year":"2019","unstructured":"Mina R, Joseph NS, Kaufman JL, Gupta VA, Heffner LT, Hofmeister CC, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 2019;125(Feb):416\u201323.","journal-title":"Cancer"},{"issue":"May","key":"587_CR11","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2008.4","volume":"22","author":"RE Tiedemann","year":"2008","unstructured":"Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(May):1044\u201352.","journal-title":"Leukemia"},{"issue":"Nov","key":"587_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0153-9","volume":"8","author":"L Sanoja-Flores","year":"2018","unstructured":"Sanoja-Flores L, Flores-Montero J, Garces JJ, Paiva B, Puig N, Garcia-Mateo A, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(Nov):117.","journal-title":"Blood Cancer J"},{"issue":"Jul","key":"587_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood.V88.1.289.289","volume":"88","author":"D Billadeau","year":"1996","unstructured":"Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood. 1996;88(Jul):289\u201396.","journal-title":"Blood"},{"issue":"Jan","key":"587_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/leu.2016.205","volume":"31","author":"WI Gonsalves","year":"2017","unstructured":"Gonsalves WI, Rajkumar SV, Dispenzieri A, Dingli D, Timm MM, Morice WG, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31(Jan):130\u20135.","journal-title":"Leukemia"},{"issue":"Feb","key":"587_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","volume":"94","author":"G An","year":"2015","unstructured":"An G, Qin X, Acharya C, Xu Y, Deng S, Shi L, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94(Feb):257\u201364.","journal-title":"Ann Hematol"},{"issue":"Jun","key":"587_CR16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","volume":"102","author":"M Granell","year":"2017","unstructured":"Granell M, Calvo X, Garcia-Guinon A, Escoda L, Abella E, Martinez CM, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102(Jun):1099\u2013104.","journal-title":"Haematologica"},{"issue":"Nov","key":"587_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0140-1","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Roeker L, Gonsalves W, Buadi F, Lacy MQ, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8(Nov):116.","journal-title":"Blood Cancer J"},{"key":"587_CR18","first-page":"3035","volume":"130","author":"NG Holtzman","year":"2017","unstructured":"Holtzman NG, Goloubeva O, Singh Z, Sawhney S, Zou Y, Yared J, et al. Plasma Cell Leukemia (PCL): clinical characteristics, outcomes, and the impact of circulating plasma cells (CPC) percentage\u2014a single center experience. Blood. 2017;130:3035. Supplement 1.","journal-title":"Blood"},{"key":"587_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-141525","volume":"136","author":"A Ge","year":"2020","unstructured":"Ge A, Huang VY, Martin T, Wolf JL, Shah N, Wong SW. Outcomes of plasma cell leukemia patients in the era of next-generation novel agents: a single-center retrospective cohort study. Blood. 2020;136:6\u20137.","journal-title":"Blood"},{"issue":"Nov","key":"587_CR20","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1038\/leu.2012.107","volume":"26","author":"SZ Usmani","year":"2012","unstructured":"Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Leukemia. 2012;26(Nov):2398\u2013405.","journal-title":"Leukemia"},{"issue":"Jun","key":"587_CR21","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-12-2043","volume":"19","author":"M Lionetti","year":"2013","unstructured":"Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res. 2013;19(Jun):3130\u201342.","journal-title":"Clin Cancer Res"},{"issue":"Oct","key":"587_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2018.09.007","volume":"73","author":"K Todoerti","year":"2018","unstructured":"Todoerti K, Calice G, Trino S, Simeon V, Lionetti M, Manzoni M, et al. Global methylation patterns in primary plasma cell leukemia. Leuk Res. 2018;73(Oct):95\u2013102.","journal-title":"Leuk Res"},{"issue":"Sep","key":"587_CR23","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","volume":"120","author":"NW van de Donk","year":"2012","unstructured":"van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood. 2012;120(Sep):2376\u201389.","journal-title":"Blood"},{"issue":"May","key":"587_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/leu.2011.312","volume":"26","author":"A Mahindra","year":"2012","unstructured":"Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012;26(May):1091\u20137.","journal-title":"Leukemia"},{"issue":"Feb","key":"587_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.23600","volume":"89","author":"E Katodritou","year":"2014","unstructured":"Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol. 2014;89(Feb):145\u201350.","journal-title":"Am J Hematol"},{"issue":"Jun","key":"587_CR26","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1093\/annonc\/mdr480","volume":"23","author":"G D'Arena","year":"2012","unstructured":"D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2012;23(Jun):1499\u2013502.","journal-title":"Ann Oncol"},{"issue":"Jan","key":"587_CR27","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/leu.2013.241","volume":"28","author":"P Musto","year":"2014","unstructured":"Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28(Jan):222\u20135.","journal-title":"Leukemia"},{"issue":"Jun","key":"587_CR28","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","volume":"34","author":"B Royer","year":"2016","unstructured":"Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a Prospective Phase II Study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2016;34(Jun):2125\u201332.","journal-title":"J Clin Oncol"},{"issue":"May","key":"587_CR29","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3324\/haematol.2009.013334","volume":"95","author":"MB Drake","year":"2010","unstructured":"Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95(May):804\u20139.","journal-title":"Haematologica"},{"issue":"Oct","key":"587_CR30","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/leu.2014.98","volume":"28","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Rajkumar SV, Gupta V, Morice WG, Timm MM, Singh PP, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma. Leukemia. 2014;28(Oct):2060\u20135.","journal-title":"Leukemia"},{"issue":"Oct","key":"587_CR31","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","volume":"106","author":"GS Nowakowski","year":"2005","unstructured":"Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(Oct):2276\u20139.","journal-title":"Blood"},{"issue":"Aug","key":"587_CR32","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bjh.13484","volume":"170","author":"D Vagnoni","year":"2015","unstructured":"Vagnoni D, Travaglini F, Pezzoni V, Ruggieri M, Bigazzi C, Dalsass A, et al. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics. Br J Haematol. 2015;170(Aug):523\u201331.","journal-title":"Br J Haematol"},{"issue":"Nov","key":"587_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0153-9","volume":"8","author":"L Sanoja-Flores","year":"2018","unstructured":"Sanoja-Flores L, Flores-Montero J, Garc\u00e9s JJ, Paiva B, Puig N, Garc\u00eda-Mateo A. et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018;8(Nov):117.","journal-title":"Blood Cancer J"},{"issue":"Jan","key":"587_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10428190601016159","volume":"48","author":"C Touzeau","year":"2007","unstructured":"Touzeau C, Pellat-Deceunynck C, Gastinne T, Accard F, Jego G, Avet-Loiseau H, et al. Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications. Leuk Lymphoma. 2007;48(Jan):207\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"Feb","key":"587_CR35","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/1042819021000029713","volume":"44","author":"M Shtalrid","year":"2003","unstructured":"Shtalrid M, Shvidel L, Vorst E. Polyclonal reactive peripheral blood plasmacytosis mimicking plasma cell leukemia in a patient with Staphylococcal sepsis. Leuk Lymphoma. 2003;44(Feb):379\u201380.","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00587-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00587-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:26:42Z","timestamp":1669901202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00587-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00587-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"18 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BP reports honoraria for lectures from and membership on advisory boards with Adaptive, Amgen, Bristol-Myers Squibb-Celgene, Creative BioLabs, Gilead, Janssen, Sanofi and Takeda; unrestricted grants from Celgene, EngMab, Roche, Sanofi, and Takeda; and consultancy for Bristol-Myers Squibb-Celgene, Janssen, Sanofi, and Takeda. LR reports honoraria from Janssen, BMS-Celgene, Amgen, Takeda, Sanofi, GSK. SZU reports grants and personal fees from Amgen, personal fees from Abbvie, grants from BMS, grants and personal fees from Celgene, personal fees from MundiPharma, grants from Pharmacyclics, grants and personal fees from Sanofi, grants and personal fees from Seattle Genetics, grants and personal fees from Janssen, grants and personal fees from Takeda, grants and personal fees from SkylineDX, grants and personal fees from Merck, grants and personal fees from GSK, outside the submitted work. FS reports honoraria from Abbvie, Amgen, BMS, Janssen, Novartis, Oncopeptides, Sanofi, Schain, SkyliteDX, Takeda; consultancy or advisory board from Celgene, Janssen, Oncopeptides, Sanofi, and unrestricted grants from Celgene, GSK, Janssen, Oncopeptides, Sanofi. SL reports honoraria or consultancy from Sorrento, Janssen, Celularity, Abbvie, GSK, Takeda, Karyopharm, Sanofi, Oncopetide and Caelum Biosciences; research grants from Karyopharm, Sanofi; and holds shares and serves on board of directors for Caelum Biosciences. EMO reports honoraria or consultancy funding from Janssen, BMS, Sanofi, GSK, Oncopeptides, Takeda, Pfizer and Amgen. LG reports consultancy or advisory boards from Takeda, Amgen, BMS\/Celgene, and Janssen. GG reports honoraria or consultancy from Fujimoto Pharmaceutical Corporation, Japan. HG reports grants and\/or provision of Investigational Medicinal Product from Amgen, BMS, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, Johns Hopkins University, Sanofi; research grants from Amgen, BMS, Celgene, Chugai, Janssen, Incyte, Molecular Partners, Merck Sharp and Dohme (MSD), Sanofi, Mundipharma GmbH, Takeda, Novartis; and consultancy or advisory boards from Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, Takeda; and honoraria from Amgen, BMS, Celgene, Chugai, GlaxoSmithKline (GSK), Janssen, Novartis, Sanofi. SAT reports grants received from Karyopharm, Sanofi Genzyme and Caelum; and honoraria from Karyopharm, Caelum, Sanofi Genzyme, Oncopeptides, and Shattuck Labs. HE reports honoria or consultancy and unrestricted grants from Janssen, BMS\/Celgene, Amgen, Novartis, Takeda, Sanofi, GSK. BGMD reports consultancy or advisory boards from Takeda, Amgen, BMS\/Celgene, and Janssen. MK reports consultancy from AbbVie, Amgen, BMS\/Celgene, GSK, Janssen, Karyopharm, Seattle Genetics, Takeda; research funding from BMS\/Celgene, Janssen; and educational or travel support from BMS\/Celgene, Janssen, and Takeda. JSM reports consultancy or advisory boards from AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, MSD, Novartis, Roche, Sanofi, Takeda, SecuraBio, and Regeneron. MVM reports honoraria or consultancy from Janssen, BMS-Celgene, Takeda, Amgen, Abbvie, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Roche, Sea-Gen, Bluebird-bio. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}